vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $11.1M, roughly 1.4× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -7.8%, a 224.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -48.8%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
DERM vs NREF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $11.1M |
| Net Profit | $-1.2M | $24.0M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | — |
| Net Margin | -7.8% | 216.6% |
| Revenue YoY | 27.3% | -48.8% |
| Net Profit YoY | -182.0% | 58.7% |
| EPS (diluted) | $-0.04 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $11.1M | ||
| Q3 25 | $17.0M | $12.5M | ||
| Q2 25 | $15.0M | $12.1M | ||
| Q1 25 | $13.1M | $11.5M | ||
| Q4 24 | $12.6M | $21.7M | ||
| Q3 24 | $14.6M | $12.5M | ||
| Q2 24 | $14.9M | $6.7M | ||
| Q1 24 | $13.0M | $-12.8M |
| Q4 25 | $-1.2M | $24.0M | ||
| Q3 25 | $-2.3M | $50.9M | ||
| Q2 25 | $-3.8M | $22.3M | ||
| Q1 25 | $-4.1M | $26.0M | ||
| Q4 24 | $1.5M | $15.2M | ||
| Q3 24 | $-2.4M | $23.3M | ||
| Q2 24 | $-3.4M | $12.1M | ||
| Q1 24 | $-10.4M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | — | ||
| Q2 25 | -19.2% | — | ||
| Q1 25 | -25.3% | — | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -19.7% | — | ||
| Q1 24 | -77.4% | — |
| Q4 25 | -7.8% | 216.6% | ||
| Q3 25 | -13.6% | 407.0% | ||
| Q2 25 | -25.3% | 184.5% | ||
| Q1 25 | -31.0% | 225.6% | ||
| Q4 24 | 12.1% | 69.9% | ||
| Q3 24 | -16.3% | 186.4% | ||
| Q2 24 | -22.6% | 179.7% | ||
| Q1 24 | -80.1% | 114.3% |
| Q4 25 | $-0.04 | $0.47 | ||
| Q3 25 | $-0.09 | $1.14 | ||
| Q2 25 | $-0.16 | $0.54 | ||
| Q1 25 | $-0.18 | $0.70 | ||
| Q4 24 | $0.10 | $0.71 | ||
| Q3 24 | $-0.12 | $0.74 | ||
| Q2 24 | $-0.17 | $0.40 | ||
| Q1 24 | $-0.53 | $-0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $31.1M |
| Total DebtLower is stronger | $25.3M | $771.2M |
| Stockholders' EquityBook value | $31.9M | $388.0M |
| Total Assets | $94.6M | $5.3B |
| Debt / EquityLower = less leverage | 0.79× | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $31.1M | ||
| Q3 25 | $24.9M | $17.9M | ||
| Q2 25 | $20.3M | $9.1M | ||
| Q1 25 | $21.1M | $19.2M | ||
| Q4 24 | $20.3M | $3.9M | ||
| Q3 24 | $22.5M | $34.7M | ||
| Q2 24 | $23.9M | $4.3M | ||
| Q1 24 | $24.1M | $13.5M |
| Q4 25 | $25.3M | $771.2M | ||
| Q3 25 | $25.2M | $720.9M | ||
| Q2 25 | $25.1M | $815.6M | ||
| Q1 25 | $25.0M | $831.5M | ||
| Q4 24 | $24.9M | $799.3M | ||
| Q3 24 | $19.8M | $815.5M | ||
| Q2 24 | $19.7M | $861.0M | ||
| Q1 24 | $14.7M | $843.3M |
| Q4 25 | $31.9M | $388.0M | ||
| Q3 25 | $25.9M | $375.4M | ||
| Q2 25 | $19.2M | $348.2M | ||
| Q1 25 | $21.5M | $343.7M | ||
| Q4 24 | $20.1M | $336.5M | ||
| Q3 24 | $10.9M | $335.8M | ||
| Q2 24 | $11.3M | $327.5M | ||
| Q1 24 | $13.0M | $327.1M |
| Q4 25 | $94.6M | $5.3B | ||
| Q3 25 | $85.2M | $5.3B | ||
| Q2 25 | $81.2M | $5.4B | ||
| Q1 25 | $85.0M | $5.4B | ||
| Q4 24 | $80.2M | $5.4B | ||
| Q3 24 | $64.0M | $5.7B | ||
| Q2 24 | $65.2M | $6.6B | ||
| Q1 24 | $66.6M | $7.1B |
| Q4 25 | 0.79× | 1.99× | ||
| Q3 25 | 0.97× | 1.92× | ||
| Q2 25 | 1.30× | 2.34× | ||
| Q1 25 | 1.16× | 2.42× | ||
| Q4 24 | 1.24× | 2.38× | ||
| Q3 24 | 1.81× | 2.43× | ||
| Q2 24 | 1.75× | 2.63× | ||
| Q1 24 | 1.13× | 2.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-4.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-4.5M | ||
| Q3 25 | $-2.4M | $8.1M | ||
| Q2 25 | $-942.0K | $3.3M | ||
| Q1 25 | $-2.8M | $16.0M | ||
| Q4 24 | $2.2M | $4.4M | ||
| Q3 24 | $-1.2M | $14.7M | ||
| Q2 24 | $-5.2M | $-7.5M | ||
| Q1 24 | $-5.0M | $17.7M |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | 1.46× | 0.29× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
NREF
Segment breakdown not available.
